Abstract 3246: Important differences between exosome biosignatures from prostate cancer patient plasma samples and prostate cancer cell lines
Teresa L. Tinder(Freeport-McMoRan (United States)), Christine Kuslich(Phoenix (United States)), Traci Pawlowski(Illumina (United States)), Unnati Jariwala, David Spetzler(Caris Life Sciences (United States)), Annemarie Tyrell, Amber Conrad(Translational Genomics Research Institute), Patrick Kennedy(Queen Mary University of London)
Cited by 0
Related Papers
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
|Journal of Hepatology|2019|364
Identification of genetic variants using bar-coded multiplexed sequencing
|Nature Methods|2008|305